BGMS Bio Green Med Solution, Inc. - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ 10-K/10-Q Agu 14, 2026
$0,96
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$0,57rendah 52m
$2,80tinggi 52m
Kapitalisasi Pasar (MRQ)
$6M
P/E
-0.1
EPS
$-6.45
Pendapatan
$0
lencana Anda
Rentang 52M
$1–$3
Peringkat Analis
HOLD
Target Harga
·
P/E
-0.1
ROE
-57.2%
Margin Laba Bersih
-200.1%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
BGMS Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$0.96
Kapitalisasi Pasar (MRQ)
$6M
P/E
-0.1
EPS
$-6.45
Pendapatan
$0
ROE
-57.2%
Rentang 52M
$1–$3
BGMS Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Pemecahan saham
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 7 Juli 2025 | 1-for-15 | Terbalik |
| 12 Mei 2025 | 1-for-16 | Terbalik |
| 18 Des. 2023 | 1-for-15 | Terbalik |
| 15 April 2020 | 1-for-20 | Terbalik |
| 31 Mei 2016 | 1-for-12 | Terbalik |
| 27 Agu 2012 | 1-for-7 | Terbalik |
| 27 Maret 2006 | 1-for-10 | Terbalik |
Tentang Bio Green Med Solution, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow.
Company overview
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.
Three product candidates are currently in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analogue, failed its Phase 3 trial for the treatment of acute myeloid leukemia (AML) in the elderly. Phase 1/2 studies are ongoing for the treatment of breast cancer and AML/MDS. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors.
Cyclacel Pharmaceuticals' ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia.
Reverse merger
After becoming the first European spin-out company to raise over $100 million in private equity, the company had to pull out of a stock market listing in July 2004. Cyclacel completed a reverse merger with Xcyte Therapies in December 2005 to acquire Nasdaq listing. This allowed Cyclacel to raise an additional $45 million in April 2006 through a private placement of stock and warrants.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
negaraMY
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$02021-12-31 → 2025-12-31
EPS$-6.452021-12-31 → 2025-12-31
Arus Kas Bebas·2021-12-31 → 2022-12-31
Margin bersih-200.1%2024-12-31 → 2024-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | BGMS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E | -0.1rata-rata 5T ≈-0.2 | ≈-0.2 | · | · | |
| P/S (TTM) | 5.8 | · | · | · | |
| P/B (MRQ) | 0.9 | · | · | · | |
| Price / Cash Flow (Harga / Arus Kas) | -1.1 | · | · | · | |
| Price / Tangible Book (Harga / Nilai Buku Berwujud) | 1.0 | · | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | BGMS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | -248.9% | · | · | · | |
| Margin Sebelum Pajak (TTM) | -196.1% | · | · | · | |
| Margin Laba Bersih (TTM) | -200.1% | · | · | · | |
| ROA | -48.8% | · | · | · | |
| ROE | -57.2% | · | · | · | |
| ROIC | -123.4% | · | · | · |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | BGMS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 8.6 | · | · | · | |
| Quick Ratio (Rasio Cepat) | 3.6 | · | · | · |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | BGMS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | -89.8% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | BGMS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.0 | · | · | · | |
| Receivables Turnover (Perputaran Piutang) | 0.0 | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
| Tanggal ex-dividen | Jumlah | Mata Uang | Imbal Hasil |
|---|---|---|---|
| Apr 29, 2025 | $36,00 | USD | ≈50.0% |
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
42.1%
Laporan Berikutnya
Nov 11, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Sep. 2024 | $-43.20 | $-135.86 | 68.2% | |
| 30 Juni 2024 | $-172.80 | $-351.29 | 50.8% | |
| 31 Maret 2024 | $-544.80 | $-1161.58 | 53.1% | |
| 31 Des. 2023 | $-1495.20 | $-1442.69 | -3.6% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $43.0K | $420.0K | $0 | $0 | $0 | · | $150.0K | · | · | · | · | |
| R&D Expense | $848.0K | $7M | $19M | $20M | $15M | $5M | $5M | $4M | · | · | · | · | |
| SG&A Expense | $8M | $5M | $7M | $7M | $7M | $6M | $5M | $5M | · | · | · | · | |
| Operating Expenses | $9M | $12M | $26M | $28M | $22M | $11M | $10M | $10M | · | · | · | · | |
| Operating Income | $-8M | $-12M | $-25M | $-28M | $-22M | $-11M | $-10M | $-10M | · | · | · | · | |
| Interest Income | · | $12.0K | $266.0K | $210.0K | $16.0K | $42.0K | $224.0K | $331.0K | · | · | · | · | |
| Other Non-op | $354.0K | $52.0K | $50.0K | $1M | $204.0K | $955.0K | $556.0K | $923.0K | · | · | · | · | |
| Pretax Income | $-3M | $-12M | $-26M | $-26M | $-22M | $-10M | $-9M | $-9M | · | · | · | · | |
| Income Tax | $7.0K | $-782.0K | $-3M | $-5M | $-4M | $-1M | $-1M | $-1M | · | · | · | · | |
| Net Income | $-3M | $-11M | $-23M | $-21M | $-18M | $-8M | $-8M | $-7M | · | · | · | · | |
| EPS (Basic) | $-6.45 | $-502.46 | $-6419.18 | $-1.90 | $-2.09 | $-3.42 | · | · | · | · | · | · | |
| EPS (Diluted) | $-6.45 | $-502.46 | $-6419.18 | $-27.24 | $-2.09 | $-3.42 | · | · | · | · | · | · | |
| Shares (Basic) | 2,185,075 | 22,314 | 3,545,000 | 11,255,677 | 8,926,173 | 3,633,385 | · | · | · | · | · | · | |
| Shares (Diluted) | 2,185,075 | 22,314 | 3,545,000 | 11,255,677 | 8,926,173 | 3,633,385 | · | · | · | · | · | · | |
| EBITDA | $-8M | $-12M | · | $-28M | $-23M | $-11M | $-10M | · | · | · | · | · |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $3M | $3M | $18M | $37M | $33M | $12M | $18M | · | · | · | · | |
| Short-term Investments | · | · | · | $5M | $4M | $5M | $11M | $17M | · | · | · | · | |
| Receivables | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $110.0K | $537.0K | $4M | $6M | $4M | $2M | $2M | $2M | · | · | · | · | |
| Other Current Assets | · | $300.0K | $341.0K | $426.0K | $79.0K | $66.0K | $103.0K | $236.0K | · | · | · | · | |
| Current Assets | $6M | $4M | $7M | $24M | $41M | $35M | $14M | $20M | · | · | · | · | |
| PP&E (Net) | $137.0K | $3.0K | $9.0K | $32.0K | $64.0K | $106.0K | $27.0K | $36.0K | · | · | · | · | |
| PP&E (Gross) | $421.0K | $427.0K | $429.0K | $415.0K | $425.0K | $991.0K | $6M | $6M | · | · | · | · | |
| Accum. Depreciation | $284.0K | $424.0K | $420.0K | $383.0K | $361.0K | $886.0K | $6M | $6M | · | · | · | · | |
| Goodwill | $2M | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $8M | $4M | $9M | $28M | $43M | $37M | $15M | $20M | · | · | · | · | |
| Accounts Payable | $617.0K | $5M | $4M | $3M | $2M | $514.0K | $890.0K | $3M | · | · | · | · | |
| Accrued Liabilities | $715.0K | $2M | $5M | $5M | $3M | $2M | $2M | $2M | · | · | · | · | |
| Current Liabilities | $1M | $6M | $8M | $8M | $5M | $2M | $2M | $4M | · | · | · | · | |
| Capital Leases | $2.0K | · | $37.0K | $106.0K | $30.0K | $1M | $1M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Total Liabilities | $1M | $6M | $8M | $8M | $5M | $4M | $4M | $5M | · | · | · | · | |
| Common Stock | $5.0K | · | · | $1.0K | $10.0K | $6.0K | $1.0K | $12.0K | · | · | · | · | |
| Paid-in Capital | $461M | $438M | $430M | $423M | $423M | $400M | $370M | $366M | · | · | · | · | |
| Retained Earnings | $-454M | $-439M | $-428M | $-406M | $-385M | $-366M | $-358M | $-350M | · | · | · | · | |
| AOCI | $-39.0K | $-891.0K | $-908.0K | $-1M | $-748.0K | $-746.0K | $-819.0K | $-760.0K | · | · | · | · | |
| Stockholders' Equity | $7M | $-2M | $607.0K | $16M | $38M | $33M | $12M | $15M | $22M | · | · | · | |
| Liabilities + Equity | $8M | $4M | $9M | $28M | $43M | $37M | $15M | $20M | · | · | · | · | |
| Shares Outstanding | 5,400,320 | 36,913 | 4,412 | 628,139 | 9,993,135 | 6,246,896 | 859,998 | 12,497,447 | · | · | · | · |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | $20.0K | $20.0K | $29.0K | · | · | · | · | |
| Stock-based Comp | $2M | $592.0K | $1M | $2M | $1M | $430.0K | $466.0K | $331.0K | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $61.0K | $-2M | · | · | · | · | · | |
| Operating Cash Flow | $-5M | $-8M | $-16M | $-21M | $-19M | $-8M | $-9M | $-7M | · | · | · | · | |
| CapEx | · | · | $6.0K | $7.0K | $27.0K | $96.0K | $10.0K | $39.0K | · | · | · | · | |
| Investing Cash Flow | · | · | $-6.0K | $-7.0K | $-27.0K | $-96.0K | $28.0K | $-39.0K | · | · | · | · | |
| Stock Issued | · | · | · | · | $4M | $30M | $4M | $630.0K | · | · | · | · | |
| Net Stock Activity | · | · | · | · | $4M | $30M | $4M | · | · | · | · | · | |
| Financing Cash Flow | $5M | $8M | $848.0K | $3M | $22M | $30M | $4M | $429.0K | · | · | · | · | |
| Net Change in Cash | $368.0K | $-241.0K | $-15M | $-18M | $3M | $22M | $-6M | $-6M | · | · | · | · | |
| Taxes Paid | $18.0K | $2.0K | $2.0K | $2.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | $-21M | $-19M | $-8M | $-9M | · | · | · | · | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -27916.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | · | -26074.4% | · | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | · | -27893.0% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | -27916.3% | · | · | · | · | · | · | · | · | · | · | |
| ROA | -48.8% | -173.8% | · | · | -43.0% | -32.4% | -44.6% | · | · | · | · | · | |
| ROE | -57.2% | 713.2% | · | · | -47.9% | -29.3% | -61.3% | · | · | · | · | · | |
| ROIC | -123.4% | 516.2% | · | · | -51.1% | -27.9% | -71.0% | · | · | · | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 0.6 | · | · | 7.7 | 14.3 | 5.8 | · | · | · | · | · | |
| Quick Ratio | 3.6 | 0.5 | · | · | 7.8 | 15.6 | 9.5 | · | · | · | · | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | · | 0.0 | · | · | · | · | · | · | · | |
| Receivables Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.27 | $-58.90 | · | · | $3.73 | $5.32 | $0.68 | · | · | · | · | · | |
| Revenue / Share | $0.00 | $0.00 | · | · | $0.00 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.18 | $-0.36 | · | · | $-2.08 | · | · | · | · | · | · | · | |
| Cash / Share | $0.65 | $84.98 | · | · | $3.66 | $5.35 | $0.69 | · | · | · | · | · | |
| EPS (TTM) | $-6.45 | $-502.46 | $-6419.18 | $-27.24 | $-2.09 | $-3.42 | · | · | · | · | · | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | -89.8% | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $43.0K | $420.0K | $0 | $0 | $0 | $823.0K | $150.0K | $823.0K | $823.0K | $823.0K | $823.0K | |
| Net Income TTM | $-3M | $-11M | $-23M | $-21M | $-18M | $-8M | $-8M | $-7M | $-8M | $-8M | $-8M | $-8M | |
| Market Cap | $8M | $3M | · | · | $139.94B | $175.64B | $829.73B | · | · | · | · | · | |
| P/E | -0.2 | -0.2 | -0.1 | -88.5 | -6700.5 | -8221.1 | · | · | · | · | · | · | |
| P/S | · | 78.3 | · | · | · | · | 1008173.4 | · | · | · | · | · | |
| P/B | 1.2 | -1.5 | · | · | 3755.6 | 5280.9 | 70935.0 | · | · | · | · | · | |
| P / Tangible Book | 1.5 | · | 1117.9 | 1897.5 | 3712.7 | 5280.9 | · | · | · | · | · | · | |
| P / Cash Flow | -1.7 | -0.4 | · | · | -7548.2 | -22137.3 | -87829.7 | · | · | · | · | · | |
| P / FCF | · | · | · | · | -7537.2 | -21872.7 | -87736.8 | · | · | · | · | · | |
| Earnings Yield | -435.8% | -550.9% | -1001.7% | -1.1% | -0.01% | -0.01% | · | · | · | · | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $357.0K | $743.0K | $-81.0K | $81.0K | · | · | $0 | $10.0K | $4.0K | $29.0K | $31.0K | $16.0K | $373.0K | $0 | $0 | $0 | |
| R&D Expense | · | · | $-47.0K | $5.0K | $68.0K | $822.0K | $880.0K | $950.0K | $2M | $3M | $4M | $5M | $5M | $6M | $7M | $4M | |
| SG&A Expense | $497.0K | $389.0K | $1M | $1M | $1M | $4M | $948.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Expenses | $754.0K | $1M | $2M | $1M | $1M | $4M | $2M | $2M | $4M | $4M | $5M | $7M | $6M | $7M | $9M | $6M | |
| Operating Income | $-418.0K | $-246.0K | $-1M | $-992.0K | $-1M | $-4M | $-2M | $-2M | $-4M | $-4M | $-5M | $-7M | $-6M | $-7M | $-9M | $-6M | |
| Interest Income | · | · | · | · | · | · | · | · | · | $2.0K | $23.0K | $50.0K | $77.0K | $116.0K | $122.0K | $67.0K | |
| Other Non-op | $31.0K | $31.0K | $333.0K | $9.0K | $2.0K | $10.0K | $0 | · | · | $52.0K | $-1.0K | $-9.0K | $-106.0K | $166.0K | $-255.0K | $14.0K | |
| Pretax Income | $-396.0K | $-167.0K | $-606.0K | $-988.0K | $-1M | $-4M | $-2M | $-2M | $-4M | $-4M | $-6M | $-7M | $-6M | $-7M | $-9M | $-6M | |
| Income Tax | $9.0K | $30.0K | $5.0K | · | $2.0K | · | $1M | $-210.0K | $-412.0K | $-1M | $-422.0K | $-668.0K | $-586.0K | $-1M | $-2M | $-1M | |
| Net Income | $-405.0K | $-197.0K | $-611.0K | $-988.0K | $-1M | $-81.0K | $-3M | $-2M | $-3M | $-3M | $-5M | $-6M | $-5M | $-6M | $-7M | $-5M | |
| EPS (Basic) | · | · | $-4.16 | $-1.31 | $-0.98 | $0.00 | $-284.21 | $-43.80 | $-172.18 | $-2.27 | · | · | $-0.44 | $-0.47 | · | $-0.42 | |
| EPS (Diluted) | · | · | $-4.16 | $-1.31 | $-0.98 | $0.00 | $-284.21 | $-43.80 | $-172.18 | $-2.27 | · | · | $-0.44 | $-7.00 | $-25.94 | $-0.42 | |
| Shares (Basic) | 5,598,701 | 5,458,564 | · | 1,912,495 | 1,360,626 | 365,231 | · | 44,681 | · | · | · | · | 12,551,794 | 12,539,189 | · | 12,314,679 | |
| Shares (Diluted) | 5,598,701 | 5,458,564 | · | 1,912,495 | 1,360,626 | 365,231 | · | 44,681 | · | · | · | · | 12,551,794 | 12,539,189 | · | 12,314,679 | |
| EBITDA | $-418.0K | $-246.0K | · | $-992.0K | $-1M | $-5M | · | $-2M | $-4M | $-4M | · | $-7M | $-6M | $-7M | · | $-6M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $6M | $3M | $3M | $6M | $10M | $11M | $18M | $24M | |
| Receivables | $1M | $1M | $1M | $725.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $972.0K | $947.0K | $1M | $1M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $133.0K | $148.0K | $110.0K | $513.0K | $108.0K | $264.0K | $537.0K | $2M | $2M | $2M | $4M | $5M | $5M | $8M | $6M | $4M | |
| Other Current Assets | · | · | · | $460.0K | $58.0K | $194.0K | · | $309.0K | $300.0K | $365.0K | $341.0K | $2M | $2M | $595.0K | $426.0K | $170.0K | |
| Current Assets | $6M | $6M | $6M | $6M | $4M | $4M | $4M | $5M | $8M | $5M | $7M | $11M | $15M | $19M | $24M | $28M | |
| PP&E (Net) | $136.0K | $138.0K | $137.0K | $129.0K | $1.0K | $1.0K | $3.0K | $4.0K | $5.0K | $7.0K | $9.0K | $16.0K | $24.0K | $31.0K | $32.0K | $37.0K | |
| PP&E (Gross) | · | · | $421.0K | · | · | · | $427.0K | · | · | · | $429.0K | · | · | · | $415.0K | · | |
| Accum. Depreciation | · | · | $284.0K | · | · | · | $424.0K | · | · | · | $420.0K | · | · | · | $383.0K | · | |
| Goodwill | $2M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $8M | $8M | $8M | $8M | $4M | $4M | $4M | $5M | $8M | $6M | $9M | $12M | $16M | $22M | $28M | $31M | |
| Accounts Payable | $189.0K | $256.0K | $617.0K | $468.0K | $221.0K | $114.0K | $5M | $4M | $5M | $5M | $4M | $2M | $2M | $3M | $3M | $983.0K | |
| Accrued Liabilities | $503.0K | $540.0K | $715.0K | $534.0K | $539.0K | $549.0K | $2M | $2M | $2M | $3M | $5M | $7M | $5M | $5M | $5M | $3M | |
| Current Liabilities | $692.0K | $796.0K | $1M | $1M | $760.0K | $663.0K | $6M | $6M | $7M | $8M | $8M | $8M | $7M | $7M | $8M | $4M | |
| Capital Leases | · | · | $2.0K | $5.0K | $10.0K | $9.0K | · | $0 | $5.0K | $21.0K | $37.0K | $52.0K | $66.0K | $80.0K | $106.0K | $107.0K | |
| Total Liabilities | $694.0K | $804.0K | $1M | $1M | $770.0K | $672.0K | $6M | $6M | $7M | $8M | $8M | $8M | $7M | $7M | $8M | $4M | |
| Common Stock | $7.0K | $5.0K | $5.0K | $3.0K | $2.0K | $204.0K | · | $2.0K | $2.0K | $1.0K | · | $12.0K | $9.0K | $9.0K | $1.0K | $9.0K | |
| Paid-in Capital | $462M | $461M | $461M | $451M | $445M | $443M | $438M | $437M | $436M | $430M | $430M | $428M | $424M | $423M | $423M | $423M | |
| Retained Earnings | $-455M | $-455M | $-454M | $-444M | $-442M | $-440M | $-439M | $-436M | $-434M | $-431M | $-428M | $-423M | $-417M | $-412M | $-406M | $-399M | |
| AOCI | · | $-30.0K | $-39.0K | · | · | · | $-891.0K | $-1M | $-915.0K | $-898.0K | $-908.0K | $-1M | $-1M | $-1M | $-1M | $-2M | |
| Stockholders' Equity | $7M | $7M | $7M | $7M | $4M | $3M | $-2M | $-970.0K | $999.0K | $-2M | $607.0K | $4M | $5M | $10M | $16M | $22M | |
| Liabilities + Equity | $8M | $8M | $8M | $8M | $4M | $4M | $4M | $5M | $8M | $6M | $9M | $12M | $16M | $22M | $28M | $31M | |
| Shares Outstanding | 6,622,794 | 5,519,456 | 5,400,320 | 3,497,537 | 1,583,965 | 207,336,389 | 36,913 | 2,152,202 | 1,805,204 | 1,318,259 | 4,412 | 12,642,822 | 12,642,822 | 12,539,189 | 628,139 | 12,539,189 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $0 | $1.0K | $655.0K | $6.0K | $7.0K | $2M | $93.0K | $107.0K | $189.0K | $203.0K | $322.0K | $391.0K | $359.0K | $401.0K | $387.0K | $389.0K | |
| Operating Cash Flow | $-352.0K | $-278.0K | $-33.0K | $-434.0K | $-1M | $-3M | $-1M | $-3M | $-3M | $-483.0K | $-4M | $-4M | $-1M | $-7M | $-5M | $-7M | |
| CapEx | $0 | $1.0K | · | · | · | · | · | $0 | · | · | $0 | $0 | $0 | $6.0K | $0 | $0 | |
| Investing Cash Flow | $0 | $-1.0K | · | · | · | · | · | $0 | · | · | $0 | $0 | $0 | $-6.0K | $0 | $0 | |
| Financing Cash Flow | $773.0K | $105.0K | $-259.0K | $-3.0K | $2M | $4M | $2M | $-1.0K | $6M | $-79.0K | $999.0K | $-50.0K | $-51.0K | $-50.0K | $42.0K | $2M | |
| Net Change in Cash | $451.0K | $-166.0K | $-333.0K | $-437.0K | $825.0K | $313.0K | $155.0K | $-3M | $3M | $-580.0K | $-3M | $-4M | $-1M | $-7M | $-5M | $-5M | |
| Taxes Paid | · | · | · | · | · | · | $0 | $0 | $0 | $2.0K | $0 | $0 | $0 | $2.0K | $0 | $0 | |
| Free Cash Flow | · | $-279.0K | · | · | · | · | · | · | · | · | · | · | · | $-7M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -4644.4% | -33.1% | · | -1224.7% | -65850.0% | -83933.3% | · | -21770.0% | -91100.0% | -15017.2% | · | -42781.2% | -1589.5% | · | · | · | |
| Net Margin | -4500.0% | -26.5% | · | -1219.8% | -65900.0% | -1350.0% | · | -19570.0% | -81425.0% | -10158.6% | · | -37700.0% | -1460.6% | · | · | · | |
| Pretax Margin | -4400.0% | -22.5% | · | -1219.8% | -65800.0% | -1350.0% | · | -21670.0% | -91725.0% | -14827.6% | · | -41875.0% | -1617.7% | · | · | · | |
| EBITDA Margin | -4644.4% | -33.1% | · | -1224.7% | -65850.0% | -83933.3% | · | -21770.0% | -91100.0% | -15017.2% | · | -42781.2% | -1589.5% | · | · | · | |
| ROA | -6.6% | -3.5% | · | -14.6% | -20.9% | -1.6% | · | -21.9% | -26.5% | -20.9% | · | -27.7% | -21.0% | -18.8% | · | -13.4% | |
| ROE | -7.5% | -4.0% | · | -32.3% | -56.9% | -18.9% | · | -117.6% | -106.2% | -74.2% | · | -45.8% | -30.8% | -26.7% | · | -16.1% | |
| ROIC | -6.0% | -4.3% | · | · | -36.3% | · | · | 202.7% | -323.8% | 135.2% | · | -143.4% | -104.2% | -58.8% | · | -24.4% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.6 | 7.1 | · | 6.4 | 5.8 | 5.6 | · | 0.8 | 1.1 | 0.6 | · | 1.4 | 2.3 | 2.6 | · | 6.4 | |
| Quick Ratio | 7.0 | 5.7 | · | 4.6 | 5.6 | 5.2 | · | 0.5 | 0.8 | 0.3 | · | 0.7 | 1.5 | 1.6 | · | 5.4 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 0.0 | 1.3 | · | 0.2 | · | · | · | · | · | · | · | · | · | · | · | · |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.08 | $1.22 | · | $2.03 | $2.29 | $0.01 | · | $-0.45 | $0.55 | $-1.67 | · | $0.34 | $0.41 | $0.81 | · | $1.76 | |
| Revenue / Share | $0.00 | $0.14 | · | $0.04 | · | · | · | · | · | · | · | · | $0.03 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-0.05 | · | · | · | · | · | · | · | · | · | · | · | $-0.55 | · | · | |
| Cash / Share | $0.57 | $0.60 | · | $1.10 | $2.70 | $0.02 | · | $1.39 | $3.32 | $2.12 | · | $0.47 | $0.80 | $0.91 | · | $1.89 | |
| EPS (TTM) | $-6.45 | $-6.45 | · | $-286.50 | $-328.99 | $-500.19 | · | · | · | · | · | $-33.80 | $-33.80 | $-33.82 | · | $-1.79 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1M | · | · | · | $43.0K | $43.0K | · | $74.0K | $80.0K | $449.0K | · | $389.0K | $373.0K | $0 | · | $0 | |
| Net Income TTM | $-2M | $-3M | · | $-5M | $-6M | $-8M | · | $-13M | $-18M | $-20M | · | $-25M | $-24M | $-23M | · | $-19M | |
| Market Cap | $6M | $6M | · | $17M | $8M | $13.93B | · | $511M | $702M | $668M | · | $15.93B | $26.85B | $25.73B | · | $65.91B | |
| P/E | -0.1 | -0.2 | · | -0.0 | -0.0 | -0.1 | · | · | · | · | · | -37.3 | -62.8 | -60.7 | · | -2936.3 | |
| P/S | 5.5 | · | · | · | 182.3 | 324023.4 | · | 6910.3 | 8773.3 | 1486.8 | · | 40951.0 | 71992.9 | · | · | · | |
| P/B | 0.8 | 0.8 | · | 2.4 | 2.2 | 4550.3 | · | -527.2 | 702.6 | -302.6 | · | 3707.2 | 5228.5 | 2535.5 | · | 2986.6 | |
| P / Tangible Book | 1.1 | 1.1 | · | 3.1 | 2.2 | 4550.3 | · | · | 702.6 | · | · | 3707.2 | 5228.5 | 2535.5 | · | 2986.6 | |
| P / Cash Flow | · | -19.9 | · | · | · | -4291.0 | · | · | · | -1382.1 | · | · | · | -3750.2 | · | · | |
| Earnings Yield | -708.8% | -645.0% | · | -5799.6% | -6646.3% | -744.3% | · | · | · | · | · | -2.7% | -1.6% | -1.7% | · | -0.03% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2023-03-31 |
|---|---|---|---|---|---|
| Pendapatan | $0 | $43.0K | $420.0K | · | · |
| Margin Operasi % | · | -27916.3% | · | · | · |
| Laba Bersih | $-3M | $-11M | $-23M | · | · |
| EPS Dilusian | $-6.45 | $-502.46 | $-6419.18 | · | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2023-03-31 |
|---|---|---|---|---|---|
| Rasio Lancar | 4.7 | 0.6 | · | · | · |
| Rasio Cepat | 3.6 | 0.5 | · | · | · |
Tidak ada data untuk laporan ini
Data fundamental belum cukup untuk membuat laporan ini.
Pemilik institusional (13F) 8 pengaju · $93K total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
8
Nilai yang dipegang
$93K
Posisi baru
1
Posisi yang keluar
3
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 1 (-2 vs Kuartal sebelumnya) | 3 (+1 vs Kuartal sebelumnya) | 4 (0 vs Kuartal sebelumnya) | 0 (0 vs Kuartal sebelumnya) | -16K |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | $68.468 | 75.240 | 73,55% | Saham |
| JANE STREET GROUP, LLC | $14.825 | 16.291 | 15,92% | Saham |
| Tower Research Capital LLC (TRC) | $5.207 | 5.722 | 5,59% | Saham |
| UBS Group AG | $3.942 | 4.332 | 4,23% | Saham |
| SBI Securities Co., Ltd. | $644 | 730 | 0,69% | Saham |
| Root Financial Partners, LLC | $6 | 7 | 0,01% | Saham |
| Archer Investment Corp | $1 | 1 | 0,00% | Saham |
| OSAIC HOLDINGS, INC. | $0 | 1 | 0,00% | Saham |
Aktivis & pemilik 5%+ 7 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Doris Wong Sing Ee ×2 pengajuan | 13 Nov. 2025 | 20,58% | Amandemen | · | SEC |
| Lazar David E. ×3 pengajuan | 8 Agu 2025 | 0,00% | Amandemen | · | SEC |
| Tang Capital Partners, LP, Tang Capital Management, LLC, Kevin C. Tang ×3 pengajuan | 22 Nov. 2017 | · | Pengajuan awal | · | SEC |
| EASTERN CAPITAL LIMITED, PORTFOLIO SERVICES LTD., KENNETH B. DART | 27 Juli 2017 | · | Pengajuan awal | Investasi pasif | SEC |
| Austin W. Marxe and David M. Greenhouse ×3 pengajuan | 3 Agu 2009 | · | Pengajuan awal | Investasi pasif | SEC |
| 13 April 2006 | · | Pengajuan awal | · | SEC | |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 12 Nov. 2004 | · | Pengajuan awal | Investasi pasif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 61 orang dalam · 20 pejabat · 26 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Doris Wong Sing Ee | Chief Executive Officer | 12 Nov. 2025 A | 1.111.131 | 0 | 0 | $0 |
| Spiro George Rombotis | President and CEO | 21 Des. 2023 P | 68.658 | 0 | 0 | $0 |
| Ronald J Berenson | President and CEO | 3 Feb. 2005 A | 430.939 | 0 | 0 | $0 |
| Cu Seng Kiu | Chief Financial Officer | 12 Nov. 2025 A | 200.000 | 0 | 0 | $0 |
| Paul Mcbarron | E. VP, Fin, CFO, COO and Secretary | 21 Des. 2023 P | 33.378 | 0 | 0 | $0 |
| Stewart Craig | COO and VP | 3 Feb. 2005 A | · | 0 | 0 | $0 |
| Brian Schwartz | Interim Chief Medical Officer | 29 Jan. 2024 A | 15.205 | 0 | 0 | $0 |
| Mark Kirschbaum | Chief Medical Officer | 30 Juni 2023 A | 31.200 | 0 | 0 | $0 |
| Judy Chiao | V.P., Clin. Dev. & Reg. Aff. | 5 Des. 2019 A | 39.024 | 0 | 0 | $0 |
| Robert Edward Sosnowski | VP, Marketing & Sales | 6 Des. 2011 A | 28.000 | 0 | 0 | $0 |
| William Collins | General Manager | 4 April 2008 A | · | 0 | 0 | $0 |
| Gregory Reyes | Senior VP, Research | 22 Des. 2007 A | 3.000 | 0 | 0 | $0 |
| Robert Westwood | V.P., Chem. & Preclin. Dev. | 21 Des. 2006 A | · | 0 | 0 | $0 |
| Robert Jackson | S.V.P. & Chief Scientific Offi | 14 Juni 2006 A | 64.841 | 0 | 0 | $0 |
| Lawrence A Romel | VP Clinical Operations | 3 Feb. 2005 A | · | 0 | 0 | $0 |
| Mark Frohlich | Medical Director and VP | 3 Feb. 2005 A | · | 0 | 0 | $0 |
| Joanna S Black | VP and General Counsel, Secret | 3 Feb. 2005 A | · | 0 | 0 | $0 |
| Kathi L Cordova | SVP Finance, Treasurer | 3 Feb. 2005 A | · | 0 | 0 | $0 |
| Mark L Bonyhadi | Vice President, Research | 3 Feb. 2005 A | · | 0 | 0 | $0 |
| Robert L Kirkman | Chief Business Officer and VP | 3 Feb. 2005 A | · | 0 | 0 | $0 |
| Avraham Ben-Tzvi | Direktur | 26 Feb. 2025 A | · | 0 | 0 | $0 |
| David Natan | Direktur | 26 Feb. 2025 A | 100.000 | 0 | 0 | $0 |
| Kenneth M. Ferguson | Direktur | 30 Juni 2023 A | 44.952 | 0 | 0 | $0 |
| Karin L Walker | Direktur | 30 Juni 2023 A | 40.602 | 0 | 0 | $0 |
| Robert J. Spiegel | Direktur | 30 Juni 2023 A | 39.415 | 0 | 0 | $0 |
| Christopher S Henney | Direktur | 30 Juni 2023 A | 39.415 | 0 | 0 | $0 |
| Sam L Barker | Direktur | 30 Juni 2023 A | 40.415 | 0 | 0 | $0 |
| Lloyd Sems | Direktur | 14 Juni 2022 A | 18.196 | 0 | 0 | $0 |
| Gregory T. Hradsky | Direktur | 15 Juni 2021 A | 2.374 | 0 | 0 | $0 |
| John Michael Middlecott Banham | Direktur | 25 Juni 2020 A | 36.847 | 0 | 0 | $0 |
| David C Uprichard | Direktur | 25 Juni 2020 A | 25.306 | 0 | 0 | $0 |
| Nicholas G Bacopoulos | Direktur | 26 Mei 2016 A | · | 0 | 0 | $0 |
| Daniel K Spiegelman | Direktur | 23 Mei 2012 A | · | 0 | 0 | $0 |
| Pierre Legault | Direktur | 19 Feb. 2008 A | · | 0 | 0 | $0 |
| John Gordon Mcvie | Direktur | 19 Feb. 2008 A | · | 0 | 0 | $0 |
| Peter Langecker | Direktur | 17 Juni 2005 A | 5.000 | 0 | 0 | $0 |
| Robert Michael Williams | Direktur | 17 Juni 2005 A | 45.700 | 0 | 0 | $0 |
| Robert Nelsen | Direktur | 17 Juni 2005 A | 2.054.271 | 0 | 0 | $0 |
| Stephen Wertheimer | Direktur | 17 Juni 2005 A | 574.363 | 0 | 0 | $0 |
| Robert E Curry | Direktur | 19 Maret 2004 X | 960.964 | 0 | 0 | $0 |
| Khai Loon Kua | Pemilik 10% | 5 Nov. 2025 J | 467.535 | 0 | 1 | $-436.459 |
| Kim Choy Yap | Pemilik 10% | 5 Nov. 2025 J | 467.535 | 0 | 6 | $-770.533 |
| Yee Lung Ong | Pemilik 10% | 5 Nov. 2025 J | 467.535 | 0 | 2 | $-487.382 |
| FITTERS Diversified Berhad | Pemilik 10% | 21 Okt. 2025 S | 279.248 | 0 | 0 | $0 |
| Lazar David E. | Pemilik 10% | 30 Juli 2025 S | 155.838 | 0 | 0 | $0 |
| MARXE AUSTIN W & GREENHOUSE DAVID M | Pemilik 10% | 23 Sep. 2011 S | 2.806.900 | 0 | 0 | $0 |
| MORGAN STANLEY | Pemilik 10% | 10 Nov. 2009 S | 2.276.852 | 0 | 0 | $0 |
| HEALTHCARE FOCUS FUND LP | Pemilik 10% | 29 Okt. 2004 P | 1.684.870 | 0 | 0 | $0 |
| Clinton Bybee | Pemilik 10% | 29 Okt. 2004 P | 2.054.271 | 0 | 0 | $0 |
| Keith Crandell | Pemilik 10% | 29 Okt. 2004 P | 2.054.271 | 0 | 0 | $0 |
| ARCH V ENTREPRENEURS FUND LP | Pemilik 10% | 29 Okt. 2004 P | 2.052.847 | 0 | 0 | $0 |
| ARCH VENTURE FUND V LP | Pemilik 10% | 29 Okt. 2004 P | 1.704.763 | 0 | 0 | $0 |
| Steven Lazarus | Pemilik 10% | 29 Okt. 2004 P | 2.054.271 | 0 | 0 | $0 |
| ARCH VENTURE FUND III L P | Pemilik 10% | 29 Okt. 2004 P | 913.784 | 0 | 0 | $0 |
| ARCH VENTURE FUND II LP | Pemilik 10% | 29 Okt. 2004 P | 1.860.824 | 0 | 0 | $0 |
| CREDIT SUISSE/ | Pemilik 10% | 19 Maret 2004 X | 960.964 | 0 | 0 | $0 |
| Dr John Francis Womelsdorf | · | 18 Nov. 2008 A | 2.100 | 0 | 0 | $0 |
| Jean Deleage | · | 1 Des. 2006 S | 0 | 0 | 0 | $0 |
| ARCH VENTURE PARTNERS V LP | · | 29 Okt. 2004 P | 1.333.934 | 0 | 0 | $0 |
| ARCH VENTURE PARTNERS LLC | · | 29 Okt. 2004 P | 913.784 | 0 | 0 | $0 |
| ARCH MANAGEMENT PARTNERS II LP | · | 19 Maret 2004 C | 1.860.824 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
BGMS Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 6 analis
JUAL
0 0,0%
Beli Kuat
0 0,0%
Beli
3 50,0%
Tahan
1 16,7%
Jual
2 33,3%
Jual Kuat
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| BGMS | $8M | -0.2 | -89.8% | · | -57.2% | · |
| ALPS | · | -50.0 | · | -41.4% | 105.3% | 32.1% |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 14, 2026